Grifols (GRFS) Operating Investment Income (2010 - 2015)
Grifols' (GRFS) quarterly Operating Investment Income came in at $106.7 million in Q4 2015, up 222.16% YoY from $33.1 million in Q4 2014, and up 148.14% on a QoQ basis from -$221.7 million in Q3 2015.
Grifols (GRFS) Operating Investment Income (2010 - 2015) Analysis & Trends
Grifols (GRFS) has 3 years of Operating Investment Income data on file, last reported at $106.7 million in Q4 2015.
- Quarterly Operating Investment Income rose 222.16% year-over-year to $106.7 million in Q4 2015, while the trailing twelve-month figure through Dec 2015 was -$109.4 million (down 2079.26% YoY) and the FY2021 annual result came in at -$283.1 million, down 140.58% from the prior year.
- Operating Investment Income advanced to $106.7 million in Q4 2015, from -$221.7 million in the prior quarter.
- In the past five years, Operating Investment Income ranged from a high of $106.7 million in Q4 2015 to a low of -$221.7 million in Q3 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Investment Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | - |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 106.73 Mn |
| Dec 31, 2015 | 106.73 Mn |
| Sep 30, 2015 | -221.69 Mn |
| Sep 30, 2015 | -221.69 Mn |
| Dec 31, 2014 | -87.37 Mn |
| Dec 31, 2014 | -87.37 Mn |
| Sep 30, 2014 | 92.90 Mn |
| Sep 30, 2014 | 92.90 Mn |
| Sep 30, 2010 | -35.16 Mn |
| Sep 30, 2010 | -35.16 Mn |